Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Study of Patients Randomized, Open, Controlled Evaluation of Autologous Tumor Tissue Antigen Sensitized DC-CIK Cells Combined With Chemotherapy in the Treatment of Patients With Esophageal Resection

NCT02644863 is registered in ClinicalTrials.gov with Shenzhen Hornetcorn Bio-technology Company, LTD as lead sponsor.

NCT NCT02644863
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02644863 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Study of Patients Randomized, Open, Controlled Evaluation of Autologous Tumor Tissue Antigen Sensitized DC-CIK Cells Combined With Chemotherapy in the Treatment of Patients With Esophageal Resection
Lead sponsor
Shenzhen Hornetcorn Bio-technology Company, LTD
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2015
Completion date
May 31, 2019
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

digestive system neoplasms, esophageal cancer, esophageal neoplasms, neoplasms